Quantity and quality of potential drug interactions with coumarin anticoagulants in the Netherlands

Pharmacy World and Science

Volumn 29, Issue 6, 2007, Pages 671-675

  Penning Van Beest, Fernie J A ^a   Koerselman, Jeroen ^a   Herings, Ron M C ^a,b  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Acenocoumarol; Antibacterial drugs; Anticoagulants; Coumarins; Drug Drug interactions; NSAIDs; Phenprocoumon; The Netherlands

Indexed keywords

ALLOPURINOL; AMIODARONE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTITHYROID AGENT; CIMETIDINE; COTRIMOXAZOLE; COUMARIN ANTICOAGULANT; DICLOFENAC; DOXYCYCLINE; FIBRIC ACID DERIVATIVE; IBUPROFEN; METRONIDAZOLE; MICONAZOLE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN UPTAKE INHIBITOR; THYROMIMETIC AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL PRACTICE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONITORING; NETHERLANDS; PHARMACY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; TIME SERIES ANALYSIS;

ADULT; AGED; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; COHORT STUDIES; COUMARINS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 35348875430     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-007-9127-x     Document Type: Article

References (18)

1. British Committee for Standards in Haemotology. Guidelines on oral anticoagulation. 3rd ed. Br J Haematol 1998;101(2):374-87.
2. Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(1 Suppl):8S-21S.
3. Sadowski JA, Booth SL, Mann KG, Malhotra OP, Bovill EG. Structure and mechanism of activation of vitamin K antagonists. London: Arnold; 1996.
4. Harder S, Thurmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 1996;30(6):416-44.
5. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165(10):1095-106.
6. Herings RMC. PHARMO: a record linkage system for postmarketing surveillance of prescription drugs in The Netherlands. Thesis. Utrecht: Utrecht University; 1993.
7. Catalan VS, Lelorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000;3(6):417-26.
8. Wittkowsky AK, Boccuzzi SJ, Wogen J, Wygant G, Patel P, Hauch O. Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacotherapy 2004;24(12):1668-74.
9. Howard PA, Ellerbeck EF, Engelman KK, Patterson KL. The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. Pharmacoepidemiol Drug Saf 2002;11(7):569-76.
10. Ufer M. Comparative pharmacokinetics of vitamin k antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005;44(12):1227-46.
11. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian study on complications of oral anticoagulant therapy. Lancet 1996;348(9025):423-8.
12. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 1996;76(1):12-6.
13. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993;95(3):315-28.
14. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001;119(1 Suppl):108S-121S.
15. Stockley IH. Drug interactions. 6th ed. London: The Pharmaceutical Press; 2002.
16. Visser LE, Penning-van Beest FJ, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, et al. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost 2002;88(5):705-10.
17. Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R. Main comedications associated with major bleeding during anticoagulant therapy with coumarins. Eur J Clin Pharmacol 2005;61(5-6):439-44.
18. Majerus PW, Tollefsen DM. Anticoagulant, thrombolytic, and antiplatelet drugs. In: Hardman JG, Goodman Gilman A, Limbird LE editors. The pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill; 2001.